ADAP - Adaptimmune's Data In Treating Solid Tumors Reinforces Prior Data And Highlights Technology Platform
Adaptimmune (ADAP) announced positive preliminary results using its SPEAR T-cell platform to treat patients with severe different types of solid tumors. These recently released results reinforce prior data in synovial sarcoma and myxoid/round cell liposarcoma ((MRCLS)), and ADP-A2M4 where 7 patients obtained a partial response ((PR)) and 4 with stable disease ((SD)) out of a total 12 evaluable patients. These two patient populations are being explored in a phase 2 study, which, ultimately, could end up receiving accelerated approval. The more pressing thing about both data sets is that it is refreshing to